华大基因CEO赵立见：从企业自主创新跃升至顶层设计 政策红利催化基因产业升级

Core Insights - The Guangzhou government has introduced a policy to accelerate the development of future industries, designating the cell and gene industry as one of the six key sectors, which is seen as a significant boost for the industry [2][3] - The CEO of BGI Genomics, Zhao Lijian, emphasizes that this policy elevates the industry from enterprise-driven innovation to government-level design, providing essential support for innovation and development in the biological sector [2][4] - BGI Genomics is leveraging local policies and resources to expand its business, including a free genetic screening program for pregnant women in Guangzhou, supported by the local government [3][5] Industry Development - The new policy is expected to enhance the transformation of new technologies in the biological sector, with BGI Genomics planning to conduct clinical trials for new diagnostic technologies in Guangzhou [4] - Despite the widespread application of genetic testing, high costs remain a barrier to accessibility; however, BGI Genomics aims to reduce costs through self-sufficiency in technology and materials [4][6] - The integration of genetic testing into medical insurance is viewed as a long-term opportunity for the industry, despite potential short-term revenue pressures [6][7] Data Assetization - The value of genetic data is increasingly recognized, with a focus on ensuring data security and compliance during the assetization process [7] - BGI Genomics is collaborating with Shenzhen Data Exchange to ensure strict data asset certification, emphasizing the importance of privacy protection [7] - The company aims to utilize genetic data to support the development of innovative drugs for rare diseases, potentially reducing treatment costs and improving early diagnosis [7][8] Future Outlook - Zhao Lijian expresses confidence in the future of the gene industry, anticipating new opportunities driven by policy support, technological innovation, and the increasing value of data [8]